Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort.
BACKGROUND
The objective of the present study was to examine the association of baseline demographic and clinical characteristics with sequentially obtained measurements of forced vital capacity (FVC), expressed as a percentage of the predicted value, and to identify predictors of the decline rate in FVC over time in the Genetics versus Environment in Scleroderma Outcome Study (GENISOS).


METHODS
To date, 266 patients have been enrolled in GENISOS, a prospective, observational cohort of patients with early systemic sclerosis. In addition to pulmonary function tests (PFTs), clinical and laboratory data were obtained from each patient. We analyzed 926 FVC measurements utilizing generalized linear mixed models. The predictive significance of baseline variables for the decline rate in FVC was investigated by the interaction term between the variable and the follow-up time within the first 3 years after enrollment as well as throughout the entire follow-up time.


RESULTS
The cohort consisted of 125 white, 54 African American, and 77 Hispanic patients with average disease duration of 2.5 years at enrollment. The mean follow-up time was 3.8 years, ranging up to 11.4 years. A number of baseline variables, including antibody status, African American ethnicity, disease type, baseline PFT values, modified Rodnan Skin Score, fibrosis on chest radiograph, and lung and skin subscores of the Severity Index, were associated with serially measured FVC levels. However, only the presence of anti-topoisomerase I antibodies (ATA) was associated with lower FVC levels (P < 0.001) as well as accelerated decline rate in FVC within the first 3 years of follow-up (P = 0.02). None of the baseline variables predicted the rate of decline in FVC on long-term follow-up. Patients with rapidly progressive ILD, however, were under-represented in the long-term follow-up group because the accelerated rate of decline in FVC was associated with poor survival (P = 0.001).


CONCLUSIONS
Presence of ATA was the only baseline variable associated with differential FVC levels, predicting the rate of decline in FVC within the first 3 years of follow-up. The association of faster decline in FVC with poor survival further emphasizes the need for identification of predictive biomarkers by collection of genetic information and serial blood samples in cohort studies.
Assassi
Shervin
S
Division of Rheumatology and Clinical Immunogenetics, University of Texas-Houston, 6431 Fannin, Houston, TX 77030, USA. Shervin.assassi@uth.tmc.edu
Sharif
Roozbeh
R
Lasky
Robert E
RE
McNearney
Terry A
TA
Estrada-Y-Martin
Rosa M
RM
Draeger
Hilda
H
Nair
Deepthi K
DK
Fritzler
Marvin J
MJ
Reveille
John D
JD
Arnett
Frank C
FC
Mayes
Maureen D
MD
D000328:Adult; D015331:Cohort Studies; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008137:Longitudinal Studies; D017563:Lung Diseases, Interstitial / Q000209:etiology* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D012129:Respiratory Function Tests; D012595:Scleroderma, Systemic / Q000150:complications* / Q000503:physiopathology; D014797:Vital Capacity
Arthritis Rheum. 2011 Oct;63(10):3078-85
21618205
Eur Respir J. 2005 Sep;26(3):511-22
16135736
J Rheumatol. 1988 Feb;15(2):202-5
3361530
Arthritis Rheum. 1988 Feb;31(2):196-203
3348823
J Rheumatol. 1995 Jul;22(7):1281-5
7562759
Eur Respir J. 2005 Oct;26(4):720-35
16204605
Arthritis Rheum. 1985 Jul;28(7):759-67
4015723
Arthritis Rheum. 1996 Jul;39(7):1151-60
8670324
Pain. 1989 Apr;37(1):51-56
2726278
J Clin Rheumatol. 2007 Aug;13(4):187-92
17762451
Arch Intern Med. 1973 Oct;132(4):506-15
4742404
J Rheumatol. 2009 Apr;36(4):773-80
19286849
Clin Rheumatol. 1997 Jun;16(4):384-90
9259253
J Rheumatol. 2009 Oct;36(10):2250-6
19723904
Arthritis Rheum. 2009 Oct 15;61(10):1403-11
19790132
Arthritis Rheum. 2009 Jan;60(1):225-33
19116937
Ann Rheum Dis. 2003 Feb;62(2):146-50
12525384
Am J Med. 1982 Sep;73(3):385-94
7124766
Eur Respir J. 2010 Jan;35(1):112-7
19541715
Arthritis Rheum. 1994 Sep;37(9):1283-9
7945490
Chest. 1998 Sep;114(3):801-7
9743170
Clin Sci. 1972 Mar;42(3):325-35
5013875
Eur Respir J. 2005 Aug;26(2):319-38
16055882
Medicine (Baltimore). 1984 Jul;63(4):221-31
6738343
Semin Arthritis Rheum. 2005 Aug;35(1):35-42
16084222
Ann Rheum Dis. 1983 Feb;42(1):23-7
6402991
Am J Respir Crit Care Med. 2008 Jun 1;177(11):1248-54
18369202
Arthritis Rheum. 2006 Aug 15;55(4):598-602
16874782
Curr Opin Rheumatol. 2003 Nov;15(6):748-55
14569205
Am J Respir Crit Care Med. 2009 Mar 1;179(5):408-13
19096004
Rheumatology (Oxford). 2003 Jan;42(1):71-5
12509616
Eur J Epidemiol. 2005;20(10):855-61
16283476
J Rheumatol. 1999 Oct;26(10):2159-67
10529133
Postgrad Med J. 1991 Jul;67(789):632-7
1924047
Arthritis Rheum. 1980 May;23(5):581-90
7378088
Ann Intern Med. 1993 Nov 15;119(10):1005-13
8214977
Am J Med. 1987 Jul;83(1):83-92
3300327
Ann Rheum Dis. 2007 Jul;66(7):940-4
17329309
J Rheumatol. 2005 Oct;32(10):1888-92
16206342
Arthritis Rheum. 2001 Jun;44(6):1363-9
11407696
Am J Med. 2005 Jan;118(1):2-10
15639201
Arthritis Rheum. 2007 Mar 15;57(2):318-26
17330281
Chest. 1994 Feb;105(2):489-95
8306752
J Rheumatol. 2007 May;34(5):1194-200
17477486
N Engl J Med. 2006 Jun 22;354(25):2655-66
16790698
Semin Arthritis Rheum. 2001 Apr;30(5):332-46
11303306